IN THE UNITED STREES PATENT AND TRADEMARK OFFICE

MAR 0 7 2006

In re application of:

Paul G. BRUNETTA, et al.

Application Serial No. 10/719,310

Filed: November 21, 2003

For: THERAPY OF NON-MALIGNANT DISEASES OR DISORDERS WITH

ANTI-ErbB2 ANTIBODIES

Examiner: Huynh, Phuong N.

Art Unit: 1644

Confirmation No. 3292

Attorney's Docket No. P1979R1

Customer No. 25213

EXPRESS MAIL LABEL NO. <u>EV 765 981 669 US</u>

DATE MAILED: MARCH 7, 2006

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

MAIL STOP AMENDMENT

Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Supplemental Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If Form Supplemental PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with M.P.E.P. §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

03/13/2006 AKELECH1 00000007 081641 10719310

02 FC:1806

180.00 DA

\Box	This sta	atement	qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):					
	<u> </u>	(1)	It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d) OR					
		(2)	It is being filed within 3 months of entry of a national stage OR					
		(3)	It is being filed before the mail date of the first Office Action on the merits OR					
		(4)	It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.					
\boxtimes	37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:							
		a certification as specified in §1.97(e) is provided below; or						
	\boxtimes	a fee of \$180.00 as set forth in \$1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.						
	37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:							
	A.	a certif	cation as specified in §1.97(e) is completed below; and					
	B.	a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and						
	C.	a fee of the pay	\$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with ment of other papers filed together with this statement.					
\boxtimes	Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Attorney's Docket No. P1979R1).							
		*	Respectfully submitted,					
Dated:	March	7, 2006	By: (Reg. No. 40,378) By: (Reg. No. 40,378)					
		H, INC						
1 DNA	-	noisso	California 94080					
		ncisco, (50) 22:	California 94080					
-	,	0) 952-9						

	Supple	emental For	m PTO-1449	Attorney's Docket No. P1979R1	P1979R1 \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\				
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				Applicant(s)	Applicant(s) Filing Date: Group Art Unit:				
				i ming bate.	•	, a.p. , a.t. C			
	(use sev	eral sheets	if necessary)	November 21, 2003	164	14			
	T 5 .	T 5 .	D	U.S. PATENT DOCUMENTS	Class	Subclass	Eiling Data		
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subciass	Filing Date (if appropriate)		
	<u></u>	<u> </u>		│ DREIGN PATENT DOCUMEN	TS	<u> </u>	<u> </u>		
Examiner	Ref.	Data	Document No.	Name	Class	Subclass	Translation		
Initials	No.	Date	Document No.	1401116	Viuss		YES NO		
IIIIIais	140.						1.20	1	
			lin alcodin	OTHER DOCUMENTS					
Evenines	Dof	Title	(incluain	g author, title, date, pertinent pa	ages, etc.)				
Examiner Initials	Ref. No.	Title		,					
	1.	De Potter, I.Y., et al., "Human EGF Receptor (HER) Family and Heregulin Members Are Differentially Expressed in Epidermal Keratinocytes and Modulate Differentiation," <i>Experimental Cell Research</i> – <u>271</u> :315-328 (2001)							
	1	Epidermai	Keratinocytes and Mo	Differentiation, Experim	n the Everessian of He	2/ 1:313-320 (/	Enidermal (Growth	
	2.	Piepkorn, M., et al., "Proliferation-Differentiation Relationships in the Expression of Heparin-Binding Epidermal Growth Factor-Related Factors and erbB Receptors by Normal and Psoriatic Human Keratinocytes," Arch Dermatol Res							
		295:93-101 (2003)							
		ļ	•			· · · · · · · · · · · · · · · · · · ·	-		
	ļ	ļ							
	-								
	-			<u></u>		<u>.</u>			
						-			
-									
							,		
	_		· · · · · · · · · · · · · · · · · · ·						
	1								
		l							
							······································		
						-	<u> </u>		

	DATE CONSIDERED:						
EXAMINER: Initial if citation considered, whether or not the citation confe	orms with MPEP 609. Draw a line through the citation if not in						
conformance and not considered. Include a copy of this form with next communication to applicant.							
the an actorisk is placed beside the reference number, a copy is not provide	led because the reference was previously cited by or submitted						

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d). SV 2191273 vI